Edaravone May Prevent Ferroptosis in ALS

Title:Edaravone May Prevent Ferroptosis in ALS

Volume: 21 Issue: 8

Author(s): Snežana Spasić*, Aleksandra Nikolić-Kokić, Srđan Miletić, Zorana Oreščanin-Dušić, Mihajlo B. Spasić, Duško Blagojević and Zorica Stević

Affiliation:

• Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, National Institute of Republic of Serbia, University of Belgrade, Belgrade,Serbia

Keywords: Edaravone, amyotrophic lateral sclerosis (ALS), ferroptosis, therapy, neurons, neurodegeneration.

Abstract: Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.

Cite this article as:

Spasić Snežana *, Nikolić-Kokić Aleksandra , Miletić Srđan , Oreščanin-Dušić Zorana , Spasić B. Mihajlo , Blagojević Duško and Stević Zorica , Edaravone May Prevent Ferroptosis in ALS, Current Drug Targets 2020; 21 (8) . https://dx.doi.org/10.2174/1389450121666200220123305